

Liaison to the WHO Stop TB Partnership

Reports to the Co-Chairs of the WHO Stop TB Partnership Working Group on New TB Drugs (WGND), one of whom is the President and Chief Executive Officer (CEO) of the TB Alliance.

Summary:

The TB Alliance is a prominent member of the WHO Stop TB Partnership Working Group on New Drugs (WGND), providing funding for WGND activities and a staff member to act as WGND Secretariat. The incumbent reports directly to the Co-Chairs of the WGND, one of whom is the TB Alliance President and CEO.

This position is designed for an individual who holds a Ph.D. in biomedical science, preferably in the infectious disease research area and has a demonstrated interest in a career in global health and /or drug development. Exceptional individuals with a Masters degree in Biology/Public Health and a minimum of 3-4 years of experience with a strong grounding in biomedical science will also be considered.

As Secretariat of the WGND, the incumbent will work with a broad range of stakeholders from the drug R & D field as well as the global health and advocacy communities. The incumbent will manage activities of the WGND and act as a liaison between the WGND and the Stop TB Partnership and the TB Alliance. The incumbent will monitor and develop knowledge on (i) advances in basic research on M. tuberculosis biology, (ii) tools developed to aid new TB drug R & D, (iii) lead compounds identified, (iv) clinical trials and regulatory processes that will impact new TB drug R & D, (v) developments in global health advocacy and (vi) the networks of centers of excellence around the world that are necessary to the development of new drugs for infectious diseases.

Some domestic and international travel will be required.

Position description:

- Project management – Initiate and execute WGND projects and activities under the direction of the WGND Leadership (Projects will range in scope from basic science knowledge development to advocacy and communications). Coordinate and track scientific progress of WGND subgroups.
- Research and surveillance – For WGND members: develop and implement a system to track, synthesize and disseminate information about advances in the drug development field, on an annual basis.
- Writing – synthesize information about WGND activities for Stop TB Partnership documents, reports, presentations, etc.
- Monitoring and evaluation – Monitor and evaluate WGND deliverables vis-à-vis the Global Plan to Stop TB: 2006 – 2015. Compile reports on progress against the Plan.
- Fundraising and budgeting – apply for funds, manage program operating budget and coordinate with funders
- Outreach – Develop and coordinate symposia, conferences, and the annual meeting; manage and administer WGND membership

Ideal candidates will have:

- A Ph.D. or equivalent degree in biomedical sciences is preferred
- 1-5 years' work experience in basic research or drug development is ideal
- Note: Exceptional individuals with a Masters degree in Biology/Public Health and a minimum of 3-4 years of experience with a strong grounding in biomedical science will also be considered.
- Outstanding organizational skills and proven ability to manage multiple projects simultaneously
- Excellent communication skills, both verbal and written
- Attention to detail and competence for establishing priorities and meeting deadlines
- Exceptional interpersonal skills to handle sensitive and confidential situations
- Demonstrated tact and diplomacy
- Ability to work independently under minimal supervision

Salary: Commensurate with education and experience.

Location: New York, NY, USA

Start date: December 2009

Please apply for this job on the TBAlliance website (www.tballiance.org), or email your application (cover letter and resume) to jobs@tballiance.org

Organizational Information:

The TB Alliance is a not-for-profit, product development partnership accelerating the discovery and development of new TB drugs that will shorten treatment, be effective against susceptible and resistant strains, be compatible with antiretroviral therapies for those HIV-TB patients currently on such therapies, and improve treatment of latent infection. The TB Alliance is committed to ensuring that approved new drug regimens are affordable, widely adopted and available to those who need them.

The Stop TB Partnership (<http://www.stoptb.org/>) was established in 2000 to realize the goal of eliminating TB as a public health problem and, ultimately, to obtain a world free of TB. It comprises a network of international organizations, countries, donors from the public and private sectors, governmental and nongovernmental organizations and individuals that have expressed an interest in working together to achieve this goal.

The Stop TB Partnership Working Group on New Drugs (http://www.stoptb.org/wg/new_drugs/) (WGND) is one of seven Working Groups of the Stop TB Partnership, focused on research and development (R & D) for new TB drugs. It is a network of more than 100 expert individuals committed to accelerating the development of effective and affordable new anti-TB therapies. The WGND acts as a forum for global collaborations and seeks to ensure close coordination of all relevant stakeholders in TB drug development. Member activities include all aspects of TB drug R&D, funding and regulatory affairs, as well as advocacy, policy-making and TB control. The WGND also serves as a mechanism through which members individually and collectively support the field of TB drug research by providing input into core publications and public policy recommendations developed by the Stop TB Partnership.